CTSO vs. INGN, TLSI, CVRX, NNOX, CV, INFU, SKIN, ELMD, BSGM, and STIM
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Inogen (INGN), TriSalus Life Sciences (TLSI), CVRx (CVRX), Nano-X Imaging (NNOX), CapsoVision (CV), InfuSystem (INFU), Beauty Health (SKIN), Electromed (ELMD), Biosig Technologies (BSGM), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
Cytosorbents vs. Its Competitors
Inogen (NASDAQ:INGN) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.
Inogen has a net margin of -7.58% compared to Cytosorbents' net margin of -25.58%. Inogen's return on equity of -13.77% beat Cytosorbents' return on equity.
Cytosorbents has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inogen had 2 more articles in the media than Cytosorbents. MarketBeat recorded 4 mentions for Inogen and 2 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.83 beat Inogen's score of 0.77 indicating that Cytosorbents is being referred to more favorably in the news media.
89.9% of Inogen shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 1.5% of Inogen shares are held by insiders. Comparatively, 7.3% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Inogen has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
Inogen currently has a consensus price target of $11.00, indicating a potential upside of 29.26%. Cytosorbents has a consensus price target of $5.50, indicating a potential upside of 507.40%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Inogen.
Summary
Inogen and Cytosorbents tied by winning 7 of the 14 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 10/17/2025 by MarketBeat.com Staff
